(-)-
Platensimycin is a potent inhibitor of
fatty acid synthase that holds promise in the treatment of metabolic disorders (e.g., diabetes and "
fatty liver") and pathogenic
infections (e.g., those caused by
drug-resistant bacteria). Herein, we describe its total synthesis through a four-step preparation of the aromatic
amine fragment and an improved stereocontrolled assembly of the ketolide fragment, (-)-platensic
acid. Key synthetic advances include 1) a modified Lieben haloform reaction to directly convert an aryl methyl
ketone into its methyl
ester within 30 seconds, 2) an experimentally improved dialkylation protocol to form platensic
acid, 3) a sterically controlled chemo- and diastereoselective organocatalytic conjugate reduction of a spiro-cyclized
cyclohexadienone by using the
trifluoroacetic acid salt of α-amino di-tert-
butyl malonate, 4) a
tetrabutylammonium fluoride promoted spiro-alkylative para dearomatization of a free
phenol to assemble the cagelike ketolide core with the moderate leaving-group ability of an early tosylate intermediate, and 5) a
bismuth(III)-catalyzed Friedel-Crafts cyclization of a free lactol, with
LiClO4 as an additive to liberate a more active oxocarbenium
perchlorate species and suppress the Lewis basicity of the sulfonyloxy group. The longest linear sequence is 21 steps with an overall yield of 3.8 % from commercially available
eugenol.